Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company advanced research and development to create novel cancer immunotherapy drugs. Regarding cash flows from operating activities, it recorded an interim net loss before income taxes, while accounts payable increased and advances decreased.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥0 million (YoY -50.0%) |
| Operating profit | ¥-1,330 million |
| Ordinary income | ¥-1,323 million |
| Profit attributable to owners of the parent | ¥-1,304 million |
| Net income per share | -¥9.39 |
| Equity ratio | End of the current fiscal period 69.6 / End of previous period 90.1 |
| Total assets | ¥1,500 million |
| Net assets | ¥1,044 million |
| Cash flows from operating activities | ¥-879,248 thousand |
| Cash flows from investing activities | ¥913 thousand |
| Cash flows from financing activities | ¥0 thousand |
| Cash and cash equivalents at end of period | ¥1,277,863 thousand |
| Full-year earnings forecast | Net Sales ¥0 million / Operating profit ¥-1,965 million / Ordinary income ¥-1,947 million / Net income ¥-1,949 million |
| Annual Dividend Forecast | 0.00 yen → 0.00 yen |
| Impairment loss | None recorded for the period (impairment loss on the interim income statement: "-") |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥659 thousand, Gain on reversal of stock acquisition rights ¥19,674 thousand / Extraordinary loss Other ¥0 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Material subsequent events | The company issued the 21st Series Stock Acquisition Rights through a third-party allotment on 5 October 2026. Of these, 37,143 rights were partially exercised between 6 October and 12 November 2026, resulting in the issuance of 3,714,300 common shares. |
| Availability of Supplementary Financial Results Materials | None |
| Availability of Financial Results Briefing | Whether applicable Available / Subject person Analysts and institutional investors |
| Issued Shares at Period-End | 138,891,300 |
| Treasury Shares at Period-End | 81 |
| Factors Behind Changes in Business Performance | The company advanced research and development to create novel cancer immunotherapy drugs. Regarding cash flows from operating activities, it recorded an interim net loss before income taxes, while accounts payable increased and advances decreased. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company states that it advanced research and development to create novel cancer immunotherapy drugs. The decrease in cash and deposits was attributed to expenditures related to research and development activities and other items. It also states that the FDA accepted the IND application for BP2202 at the end of July 2026, enabling the company to start a Phase 1 clinical trial in the United States.